Spyre Therapeutics

IL-23 plays a central role in driving chronic inflammation in #IBD, and targeting this pathway has the potential to reduce immune activation and support healing.   SPY003 is an investigational, extended half-life antibody that targets the p19 subunit of IL-23. In Phase 1 interim results, SPY003 was well tolerated and demonstrated an extended half-life that supports the potential for quarterly or twice-yearly maintenance dosing for IBD patients.   We’re building a differentiated pipeline of half-life extended antibodies designed to raise the standard of care in immune-mediated diseases, and we have six proof-of-concept readouts planned in 2026 across our SKYLINE and SKYWAY trials. Learn more and review our forward-looking statement legend at spyre.com.   MoA animation by Visual Science, 2025.

Get to know our Senior Manager of Contracts and Operations, Judy Schmitt! Judy, with a background in chemistry, really is a prime example of the deep experience and passion our team continues to bring to the table. She supports our team in contracts and patent work, streamlining tracking and requests all in house. Check out her spotlight below.

Spyre is #hiring! We're looking for an Executive Medical Director, Clinical Development to lead our clinical programs in #IBD. You'll be responsible for implementing clinical programs, ensuring scientific and medical rigor and collaborating across functions to drive program success from early development to late-stage trials. Join a collaborative, mission-driven team that challenges what’s possible and pushes forward transformative therapies with integrity and innovation. Learn more and #apply here:https://lnkd.in/eFb_Na5k

We shared Q3 2025 financial results with corporate updates, including positive interim Phase 1 results for SPY003, the initiation of Phase 2 SKYWAY basket study of SPY072, and the close of our underwritten public offering of common stock for gross proceeds of $316 million. We are on-track for 6 proof-of-concept readouts in 2026 across our SKYLINE and SKYWAY Phase 2 studies. Read more details at https://lnkd.in/ev7UDdPW

We just announced positive interim Phase 1 results from our first-in-human trial of SPY003. SPY003 is an investigational, extended half-life antibody targeting the p19 subunit of IL-23, and these encouraging results mark our fourth successful first-in-human trial readout in the past year.     SPY003 was well tolerated and exhibited an extended half-life supporting potential quarterly or twice-yearly maintenance dosing for IBD patients. We’re excited about the potential of SPY003, and the investigational combination therapies SPY130 (α4β7 + IL-23) and SPY230 (TL1A + IL-23) that it unlocks.     Read more from the study and our forward-looking statement legend: https://lnkd.in/erF-9ebV

The Spyre team is thrilled to be recognized by BioSpace’s 2026 Best Places to Work on their small employer list!     We take great pride in cultivating a superior work environment, driven by uncompromising innovation, courageous dissent, breakthrough discoveries, and an ownership mindset, with a healthy dose of fun and camaraderie mixed in!    Looking to join a stellar team? Check out our open positions at https://lnkd.in/e-sz37yJ    See the full small employer list from BioSpace:  https://lnkd.in/ef2HrY69

Spyre is #hiring two vital roles in technical operations and clinical and regulatory writing. The Director, Supply Chain will: - Lead clinical supply planning and execution by managing forecasting, packaging, labeling, distribution, and vendor oversight to ensure on-time, compliant delivery - Ensure quality and compliance, oversee documentation, budgets, and continuous improvement of GMP/GDP processes The Senior Manager, Medical Writing will: - Lead medical writing projects by managing strategy, timelines, and delivery of clear, compliant clinical and regulatory documents - Collaborate on and improve cross-functional alignment, risk management, and process optimization #Apply today at https://lnkd.in/e-sz37yJ

Blocking TL1A is expected to dampen immune signaling and promote healing of damaged tissues. SPY072 is an investigational, half-life extended monoclonal antibody targeting TL1A, and a potential first-in-class treatment for rheumatic diseases like #rheumatoidarthritis, #psoriaticarthritis, and #axialspondyloarthritis. SPY002, an investigational, half-life extended monoclonal antibody also targeting TL1A, is being examined for the potential treatment of #IBD both as a monotherapy and as part of two combination therapies. We’re developing a unique pipeline of novel antibodies engineered against validated targets in immune-mediated disease. Learn more at Spyre.com MoA animation by Visual Science, 2025.

We look forward to participating in several upcoming conferences this November, where our leadership team will engage in fireside chats and host one-on-one meetings with investors. We’ll be on site at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference in Boston, the Stifel Financial Corp. 2025 Healthcare Conference in New York, and the Jefferies Global Healthcare Conference (#JefferiesHealthcare) in London.  Investors interested in meeting with our team are encouraged to reach out. Learn more: https://lnkd.in/efHdjhga

We’ll be at American College of Rheumatology Convergence 2025 to present follow-up data from our Phase 1 study of SPY072, our potential first- and best-in-class anti-TL1A agent in development for rheumatic diseases, as well as new preclinical data that reinforce the role of TL1A as a key driver of inflammation in #arthritis. These findings further validate our approach and support the rationale for our SKYWAY Phase 2 basket study evaluating SPY072 in #rheumatoidarthritis, #psoriaticarthritis, and #axialspondyloarthritis.    Posters will be presented during the #ACR25 Congress. Details below and review our forward-looking statement legend at https://lnkd.in/eXYwBz3v